Crossing Barriers in Drug Discovery™


Plex (Latin for fold) pharmaceuticals (formerly CalAsia Pharmaceuticals) is an early stage biotechnology company which is focusing its drug discovery expertise on diseases caused by protein misfolding: ALS, Parkinson’s disease and cataracts. CalAsia Pharmaceuticals, the predecessor to Plex Pharmaceuticals, was founded in 2009 and raised almost $3,000,000 in non-dilutive funding from the NIH and the Michael J.Fox Foundation to support its efforts in fragment-based screening and structure-based drug design. Plex’s ALS effort is built around the work of Scientific Advisory Board member Dr. Arthur Horwich, Yale University School of Medicine. Dr. Horwich was one of the co-discoverers of the protein chaperone machinery, for which he received a Lasker Award. Plex pharmaceuticals additionally has a development program for Dengue, West Nile and Zika antiviral drugs which has also received support from the NIH and has worked on a novel brain-penetrant heat shock protein 90 (HSP90) inhibitor for glioblastoma.

Our Mission

Plex's mission is to accelerate seminal academic discoveries into safe and effective treatments for unmet and under-served medical needs with a focus on neurodegenerative disorders.

Drug Discovery Programs

Plex Pharmaceuticals, Inc. is a privately-held early stage pharmaceutical company focused on the rapid discovery of drug-like small molecules.

Plex's core technology platform effectively combines functional fragment screening with X-ray crystallography co-crystallization guided by a streamlined structure-based design approach to design and synthesize New Chemical Entities (NCEs) with drug-like properties.

For closely related target isotypes, Plex employs a differential fragment screening method as a powerful tool to identify highly isotype-selective and pan inhibitors to improve therapeutic efficacy.